Bacterial News and Research

RSS

PolyMedix receives FDA regulatory clearance for PMX-30063 IND application

PolyMedix, Inc. an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has received regulatory clearance from the United States Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for PMX-30063, a synthetic defensin-mimetic antibiotic.

11 Nov 2010

PolyMedix announces publication of defensin-mimetic compounds in Molecular Oral Microbiology

PolyMedix, Inc. an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, announced that data from two separate pre-clinical research studies were published in the December issue of Molecular Oral Microbiology.

10 Nov 2010

Popular antimicrobial chemicals may not be safe for human health and environment

Killing microorganisms has become a national obsession. A pair of antimicrobial compounds known as triclosan and triclocarban are lately the weapons of choice in our war of attrition against the microbial world. Both chemicals are found in an array of personal care products like antimicrobial soaps, and triclosan also is formulated into everyday items ranging from plastics and toys to articles of clothing.

10 Nov 2010

Grand Challenges Explorations projects receive new grants for tuberculosis research

Weill Cornell Medical College announced today that it was awarded two $100,000 grants from the Bill & Melinda Gates Foundation as part of the next phase of Grand Challenges Explorations, an initiative to encourage bold and unconventional ideas for global health.

10 Nov 2010

Researchers examine impact of gene mutation on Salmonella bacterium growth rate

Most mutations in the genes of the Salmonella bacterium have a surprisingly small negative impact on bacterial fitness. And this is the case regardless whether they lead to changes in the bacterial proteins or not.

9 Nov 2010

New TB-drugome may help identify protein targets for tuberculosis

Researchers at the University of California, San Diego School of Medicine and the University of Leeds have linked hundreds of federally approved drugs to more than 1,000 proteins in Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), opening new avenues to repurpose these drugs to treat TB.

9 Nov 2010

NovaBay receives $244,479 QTDP grant for program to treat Impetigo

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announced today that it has been awarded a cash grant totaling $244,479 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

9 Nov 2010

Study suggests bacterial products contribute to autoimmune diseases

Researchers are using 21st century technologies to investigate the century old hypothesis that certain autoimmune diseases, including rheumatoid arthritis, are caused by bacteria living in the human body and will present their initial data this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

Blocking beta glucuronidase enzyme could eliminate side effects of CPT-11 in colon cancer treatment

A debilitating side effect of a widely used but harshly potent treatment for colon cancer could be eliminated if a promising new laboratory discovery bears fruit.

8 Nov 2010

Advanced Life Sciences awarded $244,479.25 grant under Qualifying Therapeutic Discovery Project

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company has been awarded a cash grant under the Qualifying Therapeutic Discovery Project which was created by Congress as part of the Patient Protection and Affordable Care Act of 2010.

4 Nov 2010

Cempra to present information on solithromycin antimalarial agent at Atlanta Annual Meeting

Cempra Pharmaceuticals today announced abstracts to be presented on its novel fluoroketolide antibiotic, solithromycin (CEM-101), at the American Society of Tropical Medicine and Hygiene 59th Annual Meeting, November 3 to 7 in Atlanta. The abstracts will present new information on solithromycin's antimalarial activity. Additional data will demonstrate activity against Mycobacterium leprae.

4 Nov 2010

MicroPhage receives $977,916 QTDP grant for development of MRSA/MSSA Blood Culture Test

MicroPhage, Inc. announced today that it has received two Qualifying Therapeutic Discovery Project (QTDP) grants totaling $977,916 from the IRS. The grants, awarded as part of the Affordable Care Act, apply to small-company R&D expenditures that reduce the cost and increase the quality of healthcare in the U.S. The grants will be applied to the development of MicroPhage's first product, the MRSA/MSSA Blood Culture Test, currently under review at the FDA.

4 Nov 2010

PolyMedix receives $488,958 grants under QTDP program

PolyMedix, Inc. a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, announced today that it has been awarded two cash grants totaling $488,958 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

4 Nov 2010

Immune Network to complete patient enrollment in Phase 2b imm01 trial for tuberculosis

Immune Network Ltd. a company in the business of discovery and development of immune-based therapies, today announced that patient enrollment will be completed next week for the company's future partner Immunitor's Phase 2b imm01 trial of V5 immunotherapy in 120 patients with tuberculosis.

3 Nov 2010

Scientists recommend research on bacterial vaccine to prevent influenza

Secondary infections with bacteria such as Streptococcus pneumoniae, which causes pneumonia, were a major cause of death during the 1918 flu pandemic and may be important in modern pandemics as well, according to a new article in the Journal of Infectious Diseases co-authored by David M. Morens, M.D., senior advisor to the director of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

3 Nov 2010

AGD encourages diabetic patients to pay attention to oral health

According to the U.S. Centers for Disease Control and Prevention, diabetes affects nearly 24 million people in the United States. In observance of National Diabetes Month, the Academy of General Dentistry (AGD) encourages those with diabetes to pay extra attention to their oral health.

2 Nov 2010

Scientists use electron microscopes to study mechanism of perforin protein to punch holes in rogue cells

Scientists from the UK and Australia have seen the human immune system's assassin a protein called perforin in action for the first time. The UK team, funded by the Biotechnology and Biological Sciences Research Council (BBSRC) and the Wellcome Trust, is based at Birkbeck College where they used powerful electron microscopes to study the mechanism that perforin uses to punch holes in rogue cells.

1 Nov 2010

FDA new approvals, antibiotic and neurological drugs

Two new drugs have gained approval from the US Food and Drug Administration (FDA) – one is an antibiotic from Forest Labs and the other a first-time treatment for a neurological disorder developed by Avanir Pharmaceuticals. Another waiting for approval is Biodel's fast-acting insulin Linjeta. On the other hand seven new drugs got rejected including a diabetes drug from Amylin Pharmaceuticals and weight-loss drugs from Arena Pharmaceuticals and Vivus, respectively.

31 Oct 2010

Proteins to punch holes in cancer cells to kill them: Study

In a medical breakthrough scientists have found a protein called perforin that kills rogue cells in the human body especially the ones causing cancer. The team comprising of experts from Melbourne and London found that perforin punches holes and kills these cells. The research appeared in the acclaimed journal Nature.

31 Oct 2010

FDA approves Teflaro for treatment of community-acquired bacterial pneumonia

Forest Laboratories, Inc. announced today that Teflaro(ceftaroline fosamil), a broad-spectrum bactericidal cephalosporin with activity against both gram-positive and gram-negative microorganisms, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of community-acquired bacterial pneumonia (CABP), including cases caused by Streptococcus pneumoniae bacteremia, and acute bacterial skin and skin structure infection (ABSSSI), including cases caused by methicillin-resistant Staphylococcus aureus (MRSA).

30 Oct 2010

Bacterial News and Research

PolyMedix receives FDA regulatory clearance for PMX-30063 IND application

PolyMedix announces publication of defensin-mimetic compounds in Molecular Oral Microbiology

Popular antimicrobial chemicals may not be safe for human health and environment

Grand Challenges Explorations projects receive new grants for tuberculosis research

Researchers examine impact of gene mutation on Salmonella bacterium growth rate

New TB-drugome may help identify protein targets for tuberculosis

NovaBay receives $244,479 QTDP grant for program to treat Impetigo

Study suggests bacterial products contribute to autoimmune diseases

Blocking beta glucuronidase enzyme could eliminate side effects of CPT-11 in colon cancer treatment

Advanced Life Sciences awarded $244,479.25 grant under Qualifying Therapeutic Discovery Project

Cempra to present information on solithromycin antimalarial agent at Atlanta Annual Meeting

MicroPhage receives $977,916 QTDP grant for development of MRSA/MSSA Blood Culture Test

PolyMedix receives $488,958 grants under QTDP program

Immune Network to complete patient enrollment in Phase 2b imm01 trial for tuberculosis

Scientists recommend research on bacterial vaccine to prevent influenza

AGD encourages diabetic patients to pay attention to oral health

Scientists use electron microscopes to study mechanism of perforin protein to punch holes in rogue cells

FDA new approvals, antibiotic and neurological drugs

Proteins to punch holes in cancer cells to kill them: Study

FDA approves Teflaro for treatment of community-acquired bacterial pneumonia

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News